Natera, Inc. (NASDAQ:NTRA) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lessened its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 17.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,087 shares of the medical research company's stock after selling 56,778 shares during the quarter. Loomis Sayles & Co. L P owned approximately 0.22% of Natera worth $33,906,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. Farallon Capital Management LLC increased its stake in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock valued at $483,034,000 after purchasing an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock valued at $315,194,000 after buying an additional 85,236 shares in the last quarter. Duquesne Family Office LLC grew its stake in Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company's stock valued at $213,860,000 after acquiring an additional 45,500 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock worth $156,092,000 after acquiring an additional 246,246 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in Natera by 14.6% during the second quarter. Driehaus Capital Management LLC now owns 1,220,768 shares of the medical research company's stock valued at $132,197,000 after purchasing an additional 155,802 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In related news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction on Friday, September 13th. The stock was sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the transaction, the director now directly owns 7,969 shares in the company, valued at approximately $1,017,481.92. This trade represents a 24.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 9,682 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total value of $1,548,926.36. Following the sale, the director now owns 9,704 shares in the company, valued at approximately $1,552,445.92. This trade represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,503 shares of company stock valued at $6,325,804. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on NTRA shares. Stephens reissued an "overweight" rating and set a $125.00 target price on shares of Natera in a research note on Friday, August 9th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, August 9th. Canaccord Genuity Group boosted their price target on shares of Natera from $150.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $140.59.

Natera Trading Up 2.4 %

NTRA stock traded up $3.93 during mid-day trading on Tuesday, hitting $168.32. 968,661 shares of the company were exchanged, compared to its average volume of 1,349,196. Natera, Inc. has a 12-month low of $53.88 and a 12-month high of $171.95. The firm has a market capitalization of $22.22 billion, a P/E ratio of -93.63 and a beta of 1.53. The business has a fifty day simple moving average of $132.23 and a 200-day simple moving average of $118.64. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the firm earned ($0.95) EPS. The firm's revenue for the quarter was up 63.9% on a year-over-year basis. On average, equities research analysts predict that Natera, Inc. will post -1.66 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.